Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Servier is a French drugmaker that discovers, makes, and sells prescription medicines, mainly for cancer and heart disease.
Servier is a French medicine maker that sells prescription drugs, mostly for cancer and heart problems, to patients and doctors around the world. It is one of the biggest drug companies in France, and it is still independent and family-run — it belongs to a foundation rather than to outside shareholders. That unusual setup lets it put profits back into research instead of answering to the stock market every three months.
Its main business today is cancer. Servier has built a portfolio of cancer treatments, and a turning point came when it bought the French biotech firm Shire's oncology business and, later, the privately held U.S. cancer specialist Agios's oncology arm. Heart disease is its other traditional stronghold, with medicines like its blood-pressure and heart-failure drugs having sold in huge volumes for decades. It also sells drugs for diabetes and other conditions. A medicine is a simple business at heart: a company spends years and often billions on research, patents protect the formula, and then it sells pills and injections at a markup until cheaper copies arrive when the patent expires. The way a drugmaker actually makes money is worth understanding, because it explains both the thrill and the risk. When a new drug works, the potential is enormous, because one successful cancer treatment can sell for hundreds of thousands of dollars per patient per year. But the odds are brutal: most experimental drugs fail in testing, and the cost of those failures is paid by the few winners. Servier earns its money from doctors prescribing its approved medicines, and it chooses to focus on cancer and heart disease because those are large, growing markets where patients need long-term treatment. The company gets attention for two harder truths too. One is that drug pricing is under pressure in the U.S. and Europe, where governments and insurers push back on expensive treatments. The other is a dark chapter: Servier's diabetes drug Mediator was linked to hundreds of deaths, and the company was convicted in France over it and paid large fines and settlements. That episode reshaped its culture and its caution. Today Servier spends a big chunk of its revenue on research, aiming to replace aging products with new cancer drugs as older medicines lose patent protection.
It is a private company, so there is no stock to buy and no public dividend, and its annual sales run in the billions of euros. For a patient with cancer or a heart condition, Servier is often the name on the box — a quiet, family-owned giant that bets its future on the next breakthrough drug.
Saved answer · last researched 15 Nov 2026